Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection

Urinary Tract Infection Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of 50 mg, 100 mg and 200 mg PP4001 Twice Daily for the Treatment of Burning During Urination, Pain, and Urination Frequency Associated With Uncomplicated Urinary Tract Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01406587
• Other study ID #: PP4001.301
• Status: Completed
• Phase: Phase 2
• First received: July 26, 2011
• Last updated: October 18, 2011
• Start date: July 2011
• Est. completion date: October 2011

Study information

• Verified date: October 2011
• Source: Pinnacle Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

PP4001 is a medication not yet approved by the US FDA. This is a phase 2, multi-center, randomized, double-blind study of 3 doses of PP4001 versus placebo in the treatment of symptoms associated with uncomplicated urinary tract infection. After the screening, patients are randomized to receive one of three doses of PP4001 or placebo. Patients are screened and randomized on the same day, and take 4 doses of study drug, one dose every 12 hours. Data about uncomplicated urinary tract infection symptoms are collected from the subjects on electronic handheld devices throughout the 48-hour study period. The primary endpoint is burning during urination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 261
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Female subjects must be = 18 and = 75 years of age at the time of consent.

• Females not of childbearing potential (FNCBP) are eligible for randomization. FNCBP are defined as postmenopausal women with their last menstrual cycle (without exogenous hormone therapy) completed more than 12 consecutive months before screening or women who are surgically sterilized (hysterectomy, oophorectomy, or tubal ligation). Females of childbearing potential also are eligible for randomization provided they are not pregnant or nursing and employ appropriate methods of contraceptives for the duration of the trial. Medically acceptable forms of contraception include abstinence, oral contraceptives, intra-uterine devices, injectable hormonals, intra-vaginal rings, or double-barrier methods (condom plus spermicide), for at least 1 month prior to treatment. Subjects in a monogamous, long term relationship with a partner who has had a vasectomy at least 3 months prior to screening are also study eligible.

• Diagnosis of uncomplicated UTI as defined by having both of the following:

• Presence of supporting symptoms including new onset (within 1 week) of urination frequency, painful urination, and/or urgency.

• Positive dipstick test for leukocyte esterase.

• Demonstration of moderate to severe burning during urination as measured by a score of at least six (6) on the 11-point rating scale for Burning During Urination during screening.

• A negative urine pregnancy test for women of childbearing potential.

• If subject has a chronic, clinically stable disease that requires medication, medication to treat that disease must be stable for at least 30 days prior to screening.

• Ability to perform study procedures, including the completion of electronic diary assessments, and supply the necessary information to the study personnel as required by the protocol.

• A signed informed consent form in which the subject agrees to participate after the study has been fully explained.

Exclusion Criteria:

• Clinically significant medical history or a clinically significant abnormal finding on the physical exam, vital signs or ECG at screening, including serious acute illness (e.g. pneumonia), gastrointestinal illness that would interfere with study drug absorption, or an untreated or unstable medical illness that would likely interfere with the study assessments.

• At risk in terms of the precautions, warnings, and contraindications in the package insert for phenazopyridine hydrochloride including:

• Known hypersensitivity to phenazopyridine hydrochloride (Defined by a history of allergic or adverse response to the drug).

• Renal failure or insufficiency (Defined as having a history of abnormal renal function or as having a known renal disease).

• History of hepatic disease or failure (Defined as having known liver disease or having elevated LFTs (> 2 times the ULN) on previous laboratory testing. Patients who would not otherwise have such testing are not required to undergo special study labs).

• Known G-6-PD (glucose-6-phosphate dehydrogenase) deficiency.

• Prior use of a phenazopyridine product within 6 months of the first dose of study drug and throughout the study.

• Use of any prescription analgesic medication (e.g. opioids, prescription nonsteroidal anti-inflammatory drugs (NSAID), etc.) for urinary tract pain or other pain (headache, back pain, joint pain, dental pain, sore muscles, etc) within one and a half (1.5) dosing intervals for that medication before the firs dose of study drug, and throughout the study.

• Use of any systemic antibiotic within seven (7) days of study participation.

• Subjects with complaint of abnormal vaginal discharge.

• Current diagnosis or suspicion of complicated UTI or systemic infection based on one or more of the following:

• Known presence of an anatomic or functional abnormality.

• Presence of a urinary catheter.

• Infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound or cystoscopy.

• Clinical signs of systemic infection such as fever (oral or tympanic temperature >38 degrees Celsius), costovertebral pain or tenderness, rigors, nausea or vomiting.

• Subjects unable to comprehend the language of the informed consent and the self evaluation scales.

• Subjects who, in the opinion of the investigator, are not appropriate for, or are unable, or unwilling to undergo antibiotic treatment for uncomplicated urinary tract infection.

• Subjects with complaint of abnormal vaginal bleeding defined as different from the patient's usual menstrual period flow and timing.

• Subjects with known allergy to multivitamin or any component of the multivitamin.

• Currently participating in a clinical trial or has received an experimental drug or used an experimental device in the last 30 days prior to admission into this study.

• Subjects who, in the opinion of the investigator, are unsuitable for enrollment, unlikely to complete the course of study medication treatment, or unlikely to attend the End of Study visit.

• Subjects who are unable or unwilling to comply with the use of an electronic subject diary.

• Employees of the investigator or the institution who have direct involvement in the trial or other trials under the direction of the investigator or their associates.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Urinary Tract Infection
• Urinary Tract Infections

Intervention

Drug:
• PP4001
50 mg, 1 dose every 12 hours x 4 doses
• PP4001
100 mg, 1 dose every 12 hours x 4 doses
• PP4001
200 mg, 1 dose every 12 hours x 4 doses
• Placebo
Placebo, 1 dose every 12 hours x 4 doses

Locations

Country	Name	City	State
United States	Bellevue Family Practice/Clinical Research Advantage	Bellevue	Nebraska
United States	InvestiClin Research	Brentwood	Tennessee
United States	Tampa Bay Medical Research	Clearwater	Florida
United States	Ellipsis Research Group, LLC	Columbia	South Carolina
United States	Advanced Research Associates	Corpus Christi	Texas
United States	Soapstone Center for Clinical Research	Decatur	Georgia
United States	Hutzel Women's Health Research	Detroit	Michigan
United States	AccuMed Research Associates	Garden City	New York
United States	Palmetto Clinical Research, LLC	Greenville	South Carolina
United States	Hometown Urgent Care and Research	Groveport	Ohio
United States	Health Awareness, Inc.	Jupiter	Florida
United States	R/D Clinical Research, Inc.	Lake Jackson	Texas
United States	Clinical Research Center of Nevada	Las Vegas	Nevada
United States	Desert Clinical Research/Clinical Research Advantage	Mesa	Arizona
United States	Mesa Family Medical Center/Clincal Research Advantage	Mesa	Arizona
United States	Drug Research and Analysis Corp.	Montgomery	Alabama
United States	Central Phoenix Medical Clinic/Clinical Research Advantage	Phoenix	Arizona
United States	Wake Research Associates	Raleigh	North Carolina
United States	Northern California Research	Sacramento	California
United States	Clinical Trials of Texas	San Antonio	Texas
United States	Medical Center for Clinical Research	San Diego	California
United States	Women's Health Care Research	San Diego	California
United States	Hometown Urgent Care and Research	Springfield	Ohio
United States	Urology Center of Central Florida/Triquest Clinical Research Inc.	St. Cloud	Florida
United States	Hawthorne Medical Research, Inc.	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Pinnacle Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the efficacy of PP4001 for the relief of burning during urination as measured by the subject's self-reported score at the time of urination in women with uUTI in comparison to placebo.		Assessed at each urination from the time of randomization to 48 hours post first dose.	No
Secondary	Change from baseline in the physical exam evaluation at the End of Study visit	Body systems evaluated will include: General appearance; Skin; HEENT (Head, Ears, Eyes, Nose, Throat); Spine/Neck/Thyroid; Respiratory; Cardiovascular; Abdomen; Nervous System; Musculoskeletal	The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.	Yes
Secondary	To assess the efficacy of PP4001 for the relief of pain as measured by the subject's self-reported score at the time of urination.		Assessed at each urination from the time of randomization through 48 hours post first dose.	No
Secondary	To assess the efficacy of PP4001 for reduction in urination frequency as measured by the subject's self-reported void diary.		Assessed at each urination from the time of randomization through 48 hours post first dose.	No
Secondary	To evaluate the duration of therapeutic response to PP4001 50 mg, 100 mg and 200 mg.		Efficacy measures assessed in 2-hour windows after each dose.	No
Secondary	To assess global assessment of uUTI symptom severity and change over time as measured by the subject-reported global assessment diaries.		Assessed at each urination from the time of randomization through 48 hours post first dose.	No
Secondary	Change from baseline in vital signs at the End of Study visit	Vital sign measures will include systolic and diastolic blood pressure, pulse, respiratory rate, and temperature.	The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days after the End of Study Visit.	Yes
Secondary	Change from baseline in ECG at the End of Study visit	ECG parameters to be reported in this study include heart rate, and interval parameters of RR, PR, QRS, QT, and QTc.	The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.	Yes
Secondary	Change from baseline in laboratory evaluations at the End of Study visit	The following laboratory assessments will be performed: venous blood and urine samples for clinical laboratory testing, including hematology, serum chemistry, urinalysis, and urine culture.	The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.	Yes
Secondary	Frequency, severity and relationship to study medication of treatment emergent adverse events	Frequency of treatment emergent AEs will be calculated for each body system, by preferred term, by treatment and by period for the number of subjects reporting the event for the safety population. The severity of the AEs and the relationship to study medication will be summarized for each body system and preferred term. Withdrawals due to AEs will be summarized for each body system and preferred term.	From first dose through the End of Study Visit (48 - 100 hours post first dose)	Yes